Abstract Body

Background

Lenacapavir (LEN) is a twice-yearly injectable HIV-1 capsid inhibitor recently approved for HIV pre-exposure prophylaxis (PrEP) in the US. LEN is both a substrate and moderate inhibitor of CYP3A that may have drug-drug interactions (DDIs) with some medications. To investigate the impact of DDIs on LEN usage, we explored real-world use of medications with potential LEN DDIs among PrEP users not currently receiving LEN in the US.

Methods

HIV-1 negative individuals with ³1 dispensed oral or injectable PrEP prescription in 2024 (Jan 1 – Dec 31) were identified in the IQVIA LRxDx database. Concomitant medications were defined as prescriptions that chronologically overlapped with a PrEP prescription. Medications with potential LEN DDIs were categorized by type of interaction with LEN and recommended action: 1) strong or moderate CYP3A inducers requiring LEN dose modification, 2) sensitive substrates of CYP3A or P-gp requiring monitoring for side effects or possible dose reductions, or 3) no interaction expected and no dose adjustments needed. Individuals taking multiple concomitant medications were included under the highest level of DDI they received. Overall frequency of use, and frequency and duration of concomitant use were assessed for medications in each LEN DDI level.

Results

Among 457,402 PrEP users (mean age: 38 years; 91% males) in 2024, 84% had used at least one concomitant medication, with doxycycline hyclate (30.1%) being most common. In total, 118,531 PrEP users (26%; mean age: 46; 92% males) had concomitant use of medications with potential LEN DDIs, including 0.5% requiring LEN dose modification and 12.6% requiring monitoring for side effects/dose reductions (Table). Concomitant medications requiring LEN dose modifications were most often oxcarbazepine (0.3% of all PrEP users), carbamazepine (0.1%) and rifampin (<0.1%). Medications requiring monitoring were most often erectile dysfunction (ED) medications (10.7%), e.g., tadalafil (7.5%), sildenafil (4.1%), and vardenafil (0.1%). 

Conclusions

While use of concomitant medications was common among people taking PrEP in the US, the vast majority (>99%) would not require LEN dose adjustment. A minority (<15%) would require side effect monitoring or consideration of dose reduction, and most of these were ED medications. These findings underscore the feasibility of LEN use across real-world PrEP users, including those using concomitant medications.

Table or Figure